

## Vancocin (vancomycin) Capsules

### Policy Number: C5325-C

**CRITERIA EFFECTIVE DATES:**

ORIGINAL EFFECTIVE DATE	LAST REVIEWED DATE	NEXT REVIEW DATE
06/2013	12/2018	12/2019
J CODE	TYPE OF CRITERIA	LAST P&T APPROVAL
NA	RxPA	Q2

**PRODUCTS AFFECTED:** Vancocin (vancomycin) Capsules**DRUG CLASS:** Glycopeptides**ROUTE OF ADMINISTRATION:** Oral**PLACE OF SERVICE:**

Retail Pharmacy

**AVAILABLE DOSAGE FORMS:** vancomycin 125mg cap, 250mg cap, Vancocin 125mg cap, 250mg cap**FDA-APPROVED USES:** indicated for the treatment of C. difficile-associated diarrhea. Vancocin capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).**COMPENDIAL APPROVED OFF-LABELED USES:** None

---

**COVERAGE CRITERIA: INITIAL AUTHORIZATION****DIAGNOSIS:** C. difficile-associated diarrhea.**REQUIRED MEDICAL INFORMATION:****A. PSEUDOMEMBRANOUS COLITIS DUE TO C. DIFFICILE:**

1. The patient has the diagnosis of Clostridium difficile-associated diarrhea (CDAD) confirmed by a positive stool assay  
AND
2. The patient has experienced inadequate treatment response to PREFERRED formulary product (First- Vanc or Firvanq)

**DURATION OF APPROVAL:** Initial authorization: up to 14 days, Continuation of therapy: NA**QUANTITY:** 125 mg PO 4 times daily for 10 days (for fulminant cases, 500 mg PO or via nasogastric tube 4 times daily)**PRESCRIBER REQUIREMENTS:** None**AGE RESTRICTIONS:** None**GENDER:**

Male and female

**CONTINUATION OF THERAPY:** NA

**CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:** All other uses of Vancocin (vancomycin) Capsules are considered experimental/investigational and therefore, will follow Molina's Off-Label policy

**OTHER SPECIAL CONSIDERATIONS:** None

**BACKGROUND:** None

**APPENDIX:** None

---

**REFERENCES:**

1. Vancocin Capsules [package insert]. Baudette, MN: Ani Pharmaceuticals Inc.; August 2014.
2. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed December 2016.
3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription].
4. Cohen S, Gerding D, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology 2010;31:431-455.
5. Zar F, Bakkanagari S, Moorthi S, Davis M. A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease Severity. Clinical Infectious Diseases 2007;45:302-307.
6. Centers for Disease Control. Clostridium difficile Infection. Available at [http://www.cdc.gov/HAI/organisms/cdiff/Cdiff\\_infect.html](http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_infect.html).
7. Gould C, McDonald C. Bench-to-bedside review: Clostridium difficile colitis. Critical Care 2008;12:203-211.
8. Safety and Efficacy of Fidaxomicin in the Treatment of Clostridium Difficile-associated Diarrhea. Available at [http://www.medscape.com/viewarticle/774585\\_1-1](http://www.medscape.com/viewarticle/774585_1-1)